DUBLIN, June 24, 2022 /PRNewswire/ — The “Middle East Precision Medicine Market – Country Analysis: Focus on Ecosystem, Technology, Application, End User and Country Data – Analysis and Forecast, 2022-2032” report has been added to from ResearchAndMarkets.com offer.
The Middle East The precision medicine market was estimated at $3,942.6 million in 2021, which is expected to grow with a CAGR of 7.37% and reach $8,620.0 million by 2032.
The Middle East The precision medicine market is expected to experience high growth, attributed to the increasing prevalence of chronic diseases, advances in sequencing technologies, reduction of adverse drug reactions through pharmacogenomic testing, and potential for overall cost reduction health care around the world.
Large and continuous investments by healthcare companies to meet industry demand and increasing adoption of precision medicine by major end-users are the major factors propelling the growth of the Middle East precision medicine market.
Market life cycle stage
Precision medicine refers to medicine developed according to an individual’s genetic profile. It provides advice regarding the prevention, diagnosis and treatment of disease.
Population segmentation is done based on the genome structure of individuals and their compatibility with a specific drug molecule. In the precision medicine market, the application of molecular biology is to study the cause of a patient’s illness at the molecular level so that targeted therapies or individualized therapies can be applied to cure the health problems of the patient. patient.
This industry is gaining momentum owing to the growing awareness of individuals about healthcare, the integration of smart devices such as smartphones and tablets in healthcare, and the increasing collaborations and agreements of technology companies. information (IT) with diagnostic and biopharmaceutical companies for the development of precision diagnostic tools.
The growth of the precision medicine market over the past few years has been monumental. New technologies are rapidly being introduced, expanding the arsenal of accessible tools to support the development and adoption of precision medicine solutions versus “one size fits all” therapies.
Advances in gene therapies, cell therapies, molecular biomarker analysis and companion diagnostics have the potential to transform medicine and increase the ability to treat and cure several incurable diseases. Advances in sequencing technologies and non-invasive diagnostics, such as liquid biopsy and non-invasive prenatal testing (NIPT), have facilitated real-time data acquisition and generated interest in their use in data acquisition. by showing the biology of tumors and metastatic tissues.
The presence of major service providers of precision medicine products in Middle East regions has a major impact on the market. For example, Illumina, Inc. provides NovaSeq 6000 S2 Reagent Kit, NovaSeq 6000 S4 Reagent Kit, and NovaSeq Xp 4-Way Kit in the Middle East.
Companies such as F. Hoffmann-La Roche Ltd provide liquid foundation. Services are a reliable and convenient way to extend in-house resources with perfectly matched bioinformatics expertise and services that ensure quality results. The presence of these companies has a positive impact on the growth of the market.
Impact of COVID-19
The stream Middle East The precision medicine market study includes products and applications used to deliver beneficial effects to specific health benefits and treatments. Since the market is mainly dominated by applications and ecosystems, the COVID-19 pandemic has had little impact on the growth or revenue generated by the market.
The current market valuation has taken into consideration the insights provided by major market opinion leaders from both the supply side and the demand side. The majority of products, such as kits and tests on the market, are used for infectious disease applications. Additionally, infectious diseases play an important role in the growth of the market.
Recent Developments in the Middle East Precision Medicine Market
In October 2020, Bio-Rad Laboratories has launched the CFX Opus 96 Dx System and the CFX Opus 384 Dx System. The product can multiplex nearly approximately five samples to provide efficient in vitro diagnostic (IVD) test development and testing. The product was marketed in the Middle East Region.
In March 2021F. Hoffmann-La Roche Ltd has launched the AVENIO Tumor Tissue CGP kit, which allows laboratories to extend their oncology research in-house.
In June 2019F. Hoffmann-La Roche Ltd has partnered with the Health Authority and an international health insurer, AXA, to dubai. This partnership would expand funding for the diagnosis and treatment of breast, colorectal and cervical cancer.
Key Market Players and Competition Summary
The companies profiled have been selected based on input gathered from primary experts and analysis of company coverage, product portfolio and market penetration.
Some of the most prominent established names in this market are:
Bio-Rad Laboratories, Inc.
Diginova Health Solutions Ltd.
F. Hoffmann-La Roche SA
Diginova Health Solutions Ltd.
Thermo Fisher Scientific Inc.
Main topics covered:
1 Middle East Precision Medicine Market
2 Market Overview
2.1 Market definition
2.2 Precision medicine: a frontier in the genesis of patient-centered medicine
2.3 Precision medicine: reshaping one-size-fits-all theory into personalized therapy
2.4 Precision medicine: enabling technologies and applications
126.96.36.199 3D DNA printing
188.8.131.52 4D molecular imaging
2.4.2 Early adopters
184.108.40.206 Clustered regularly spaced short palindromic repeats (CRISPR)
220.127.116.11 Imaging computing
2.4.3 Early majority
18.104.22.168 Artificial Intelligence (AI)
22.214.171.124 Circulating Free DNA (cfDNA)
126.96.36.199 Big Data
188.8.131.52 Next Generation Sequencing (NGS)
184.108.40.206 Health informatics
2.4.4 Late Majority
220.127.116.11 Polymerase chain reactions (PCR)
2.5 Impact of COVID-19 on the Middle East Precision Medicine Market
3 Industry Outlook
3.1 Patent Analysis
3.2 Legal requirements and regulations
4 Competitive landscape
4.1 Synergistic activities
4.2 Product launches, enhancements and upgrades
4.3 Mergers and Acquisitions
4.4 Business expansion
5 Market dynamics
5.1 Market Drivers
5.1.1 Advancement of sequencing technologies
5.1.2 Growing prevalence of chronic diseases
5.1.3 Shifting the importance in medicine from reaction to prevention
5.1.4 Reducing Adverse Drug Effects with Pharmacogenomics Testing
5.1.5 Global Healthcare Cost Reduction Potential
5.2 Market Constraints
5.2.1 Unified framework for data integration
5.2.2 Limited knowledge of molecular mechanism/interaction
5.2.3 Lack of a strong reimbursement landscape
5.3 Market Opportunities
5.3.1 Targeted gene therapy
5.3.2 Expansion into emerging markets
5.3.3 Collaborations and partnerships across the value chain to accelerate market entry
6 Middle East Precision Medicine Market, by Ecosystem, USD Million, 2021-2032
6.2 Applied sciences
6.3 Precision therapy
6.4 Digital health and information technology
6.5 Accuracy diagnostics
7 Middle East Precision Medicine Market, by Application, USD Million, 2021-2032
7.3 Infectious diseases
7.8 Other applications
8 Middle East precision medicine market, by end-user, USD million, 2021-2032
8.2 Biopharmaceutical companies
8.3 Diagnostic companies
8.4 Other end users
9 Middle East Precision Medicine Market, by Country, USD Million, 2021-2032
9.1.7 Other countries
10 Market – Competitive Benchmarking and Company Profiles
For more information on this report, visit https://www.researchandmarkets.com/r/g8senx
Research and Markets
For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900
US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716
Show original content:https://www.prnewswire.com/news-releases/middle-east-8-62-billion-precision-medicine-markets-to-2032-targeted-gene-therapy–expansion-into-emerging-markets-presents -opportunities-301574856.html
SOURCE Research and Markets